CM-24
Based on 1 Customer Validation
CM-24 (MK-6018) is a highly selective humanized monoclonal antibody targeting CEACAM1/CD66a. CM-24 binds to the N-terminal domain of CEACAM1, blocks the CEACAM1-CEACAM1 interaction, relieves the co-inhibitory effect on CEACAM1-positive lymphocytes, and enhances the cytotoxic activity of TIL, LAK and NK cells against CEACAM1-positive tumor cells. CM-24 can be used in studies related to tumor immunology, tumor metastasis and thrombosis. For the isotype control of CM-24, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 96.02%
- CAS No.: 1783801-93-3
- 분자량:144.98 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
CEACAM1 |
In Vitro
CM-24 (MK-6018) (0.1-10 μg/mL; pre-treated for 30 min followed by 24 h co-culture) dose-dependently enhances the cytotoxic activity of human LAK cells against SK-MEL-28 melanoma cells[2].
CM-24 (0.1-10 μg/mL; 30 min pre-treatment followed by 24 h co-culture) enhances the cytotoxic activity of LAK cells against T3M4, SU8686 and PANC2 pancreatic cancer cells as well as H358 and H460 lung cancer cells, and increases the secretion of Granzyme B and IFNγ[2].
CM-24 (20 μg/mL; 1 h) specifically binds to NET structures formed by PMA (HY-18739)-stimulated primary human neutrophils, while no detectable staining is observed with the human IgG4 isotype control[3].
CM-24 (500 μg/mL; 24-48 h) inhibits NETs (20 ng/μL)-induced migration of SK-MEL-28, A549 and AsPC-1 cells by 69.5%, 82.7% and 49.1%, respectively[3].
CM-24 (500 μg/mL; pre-treated for 30 min followed by 2 h of incubation) significantly reduces the adhesion of CEACAM1-positive SK-MEL-28 cells to 4 ng/μL NETs[3].
CM-24 (500 μg/mL; 30 min pre-treatment) reduces platelet aggregation induced by 5 and 10 ng/μL fresh NETs by 70% and 53%, respectively, compared with IgG4 isotype control[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SK-MEL-28, A549 and AsPC-1 cells
-
Concentration:CM-24: 500 μg/mL; NETs: 20 ng/μL
-
Incubation Time:SK-MEL-28/A549: 24 h; AsPC-1: 48 h
-
Result:Inhibited NET-induced migration by 69.5%, 82.7% and 49.1%, respectively.
-
Cell Line:NETs generated from PMA-stimulated primary human neutrophils
-
Concentration:CM-24: 20 μg/mL; PMA: 100 nM
-
Incubation Time:NET induction: 4 h; CM-24 staining: 1 h
-
Result:Specifically bound NET structures, whereas isotype control showed no detectable staining.
In Vivo
Combination of CM-24 (1-10 mg/kg; i.v.; twice weekly) with melanoma-reactive TIL reduces the median number of lung lesions to 5, 6, 3, and 2, respectively, compared with 45 in the TIL plus control IgG group[2].
CM-24 (25-100 mg/kg; intravenous infusion; once every 2 weeks; 4 doses administered over 6 weeks) causes no treatment-related toxicity, mortality or pathological changes in rhesus monkeys[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Intravenous MEL526 melanoma lung metastasis model with adoptively transferred melanoma-reactive TILs[2]
-
Dosage:1, 3, 6 and 10 mg/kg
-
Administration:CM-24: i.v., twice weekly for 44 days; TILs: i.v., every 10 days
-
Result:Produced TGI values of 84%, 87%, 90% and 93%, respectively; statistical significance was observed at 6 and 10 mg/kg.
-
Animal Model:Intravenous MEL526 melanoma lung metastasis model[2]
-
Dosage:1, 3, 6 and 10 mg/kg
-
Administration:i.v., twice weekly; combined with TILs
-
Result:Reduced median lung lesion counts to 5, 6, 3 and 2, respectively, compared with 45 in the TIL plus control IgG group.
-
Animal Model:TIL receptor-occupancy assessment in lung lesions[2]
-
Dosage:1, 3, 6 and 10 mg/kg
-
Administration:i.v., twice weekly
-
Result:Produced approximately 50% CEACAM1 receptor occupancy at 1 mg/kg and >90% occupancy at 3, 6 and 10 mg/kg.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CEACAM1 Protein, Human can bind CM-24. The EC50 for this effect is 3.38 ng/mL. -
Flow cytometric analysis of 1.5X106 HT-29 cells with CM-24 (HY-P990569, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1783801-93-3
-
Appearance Liquid
-
분자량 144.98 kDa
-
Color Colorless to light yellow
-
Synonyms
MK-6018
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CM-24 Related Classifications
HY-P990569 Related Classifications
Powered by Bioz